Literature DB >> 6424437

Factor VIII: structure and function in blood clotting.

S I Chavin.   

Abstract

Factor VIII (antihemophilic factor) is the protein that is deficient or defective in patients with classical hemophilia and Von Willebrand syndrome. Factor VIII in plasma is thought to be associated in a complex with the highest molecular weight multimers of another glycoprotein, Von Willebrand protein. Highly purified human factor VIII appears to have an Mr of between 200,000 and 300,000 and to consist of several polypeptide chains. The concentration of factor VIII in plasma is around 100-200 ng/ml, equivalent to around 1 nM. The purified proteins retain one or more of the known properties of factor VIII, including the acceleration of factor IXa-mediated activation of factor X, ability to be activated by thrombin and factor Xa, inactivation by activated protein C, and by human antibodies to factor VIII. Among the known clotting factors, factors VIII and V are exceptional in not possessing enzymatic activity. Factors IXa and VIII and X appear to form a functional complex, all of which need to be present and active simultaneously for optimal activation of factor X. The mechanism by which factor VIII promotes activation of factor X by factor IXa is not known, but the major effect is to increase the rate of the reaction. Following treatment of factor VIII with thrombin, a new and smaller polypeptide Mr around 70,000 +/- 5,000 is produced. Factors IXa and Xa also have been reported to activate factor VIII. It is not known whether limited proteolytic cleavage is required absolutely for the expression of factor VIII activity or if it only increases an activity already expressed by the uncleaved protein. Factor VIII is inactivated by thrombin and by activated protein C. Thus, factor VIII can be modulated by at least four of the serine proteases in the clotting system. A major goal for future research is to increase our understanding of the role in blood clotting played by factor VIII, and to apply this information to clinical problems which result from inherited abnormalities of factor VIII.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424437     DOI: 10.1002/ajh.2830160312

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  The effects of desmopressin on hemostatic parameters in the normal dog.

Authors:  I B Johnstone; S Crane
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

2.  Hemostatic studies in a newfoundland dog with idiopathic epistaxis.

Authors:  I B Johnstone; M Macleod
Journal:  Can Vet J       Date:  1988-01       Impact factor: 1.008

3.  The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.

Authors:  I B Johnstone; S Crane
Journal:  Can J Vet Res       Date:  1987-04       Impact factor: 1.310

4.  Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.

Authors:  Q Shi; E L Kuether; J A Schroeder; C L Perry; S A Fahs; J Cox Gill; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

Review 5.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

6.  Canine Von Willebrand's Disease: A Common Inherited Bleeding Disorder in Doberman Pinscher Dogs.

Authors:  I B Johnstone
Journal:  Can Vet J       Date:  1986-09       Impact factor: 1.008

Review 7.  Mechanisms of thrombosis in ANCA-associated vasculitis.

Authors:  Durga Prasanna Misra; Koshy Nithin Thomas; Armen Yuri Gasparyan; Olena Zimba
Journal:  Clin Rheumatol       Date:  2021-06-09       Impact factor: 2.980

Review 8.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

9.  Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing.

Authors:  Xinfu Zhang; Weiyu Zhao; Giang N Nguyen; Chengxiang Zhang; Chunxi Zeng; Jingyue Yan; Shi Du; Xucheng Hou; Wenqing Li; Justin Jiang; Binbin Deng; David W McComb; Robert Dorkin; Aalok Shah; Luis Barrera; Francine Gregoire; Manmohan Singh; Delai Chen; Denise E Sabatino; Yizhou Dong
Journal:  Sci Adv       Date:  2020-08-21       Impact factor: 14.136

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.